4.8 Article

Activated ERBB2/HER2 Licenses Sensitivity to Apoptosis upon Endoplasmic Reticulum Stress through a PERK-Dependent Pathway

期刊

CANCER RESEARCH
卷 74, 期 6, 页码 1766-1777

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-13-1747

关键词

-

类别

资金

  1. Ministerio de Ciencia e Innovacion, Red Tematica de Investigacion Cooperativa en Cancer [SAF2009-07163, SAF2012-32824, SAF2010-20519, RTICC: RD06/0020/0068, RD12/0036/0026, RD12/0036/0029]
  2. European Community through the regional development funding program (FEDER)
  3. Junta de Andalucia [P09-CVI-4497]
  4. NIH [CA155413]
  5. Ministerio de Economia y Competitividad (MINECO)
  6. Junta de Andalucia
  7. MINECO

向作者/读者索取更多资源

HER2/Neu/ERBB2 is a receptor tyrosine kinase overexpressed in approximately 20% of human breast tumors. Truncated or mutant isoforms that show increased oncogenicity compared with the wild-type receptor are found in many breast tumors. Here, we report that constitutively active ERBB2 sensitizes human breast epithelial cells to agents that induce endoplasmic reticulum stress, altering the unfolded protein response (UPR) of these cells. Deregulation of the ERK, AKT, and mTOR activities elicited by mutant ERBB2 was involved in mediating this differential UPR response, elevating the response to endoplasmic reticulum stress, and apoptotic cell death. Mechanistic investigations revealed that the increased sensitivity of mutant ERBB2-expressing cells to endoplasmic reticulum stress relied upon a UPR effector signaling involving the PERK-ATF4-CHOP pathway, upregulation of the proapoptotic cell surface receptor TRAIL-R2, and activation of proapoptotic caspase-8. Collectively, our results offer a rationale for the therapeutic exploration of treatments inducing endoplasmic reticulum stress against mutant ERBB2-expressing breast tumor cells. (C) 2014 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据